(a)
(b)
(c)

Figure 8: FSM downregulates the detrimental accumulation of AGEs, MDA, and NO after 42-d treatment (72 d of total duration of diabetes). (a) The serum level of AGEs; (b) the serum level of MDA; (c) the serum level of NO. Values are presented as mean ± SD, n=8. p < 0.05, p < 0.01: untreated diabetic model group, CaD group, FSM high-dose, FSM medium-dose, and FSM low-dose group vs normal group; #p < 0.05, ##p < 0.01: CaD group, FSM high-dose, FSM medium-dose, and FSM low-dose group vs untreated diabetic model group.